Literature DB >> 32520664

Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review.

Olivia A Charlton1,2, Victoria Harris3, Kevin Phan4, Erin Mewton1, Chris Jackson2,5, Alan Cooper1,2.   

Abstract

Significance: Toxic epidermal necrolysis (TEN) and Steven-Johnson syndrome (SJS) are potentially fatal acute mucocutaneous vesiculobullous disorders. Evidence to date suggests that outcomes for patients with both TEN and SJS are largely dependent on stopping the causative agent, followed by supportive care and appropriate wound management in a specialized burns unit. These are life-threatening conditions characterized by widespread full-thickness cutaneous and mucosal necrosis. This article outlines the approach to holistic management of such patients, in a specialized unit, highlighting various practical aspects of wound care to prevent complications such as infection, mucosal and adhesions, and ocular scaring. Recent Advances: There is improved understanding of pain and morbidity with regard to the type and frequency of dressing changes. More modern dressings, such as nanocrystalline, are currently favored as they may be kept in situ for longer periods. The most recent evidence on systemic agents, such as corticosteroids and cyclosporine, and novel treatments, are also discussed. Critical Issues: Following cessation of the culprit trigger, management in a specialized burns unit is the most important management step. It is now understood that a multidisciplinary team is essential in the care of these patients. Following admission of such patients, dermatology, ear, nose, and throat surgery, ophthalmology, urology, colorectal surgery, and gynecology should all be consulted to prevent disease sequelae. Future Directions: Looking forward, research is aimed at achieving prospective data on the efficacy of systemic immunomodulating agents and dressing types. Tertiary centers with burns units should develop policies for such patients to ensure that the relevant teams are consulted promptly to avoid mucocutaneous complications.

Entities:  

Keywords:  Steve–Johnson syndrome; drug reaction; toxic epidermal necrolysis

Mesh:

Substances:

Year:  2020        PMID: 32520664      PMCID: PMC7307670          DOI: 10.1089/wound.2019.0977

Source DB:  PubMed          Journal:  Adv Wound Care (New Rochelle)        ISSN: 2162-1918            Impact factor:   4.730


  101 in total

1.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.

Authors:  S Bastuji-Garin; N Fouchard; M Bertocchi; J C Roujeau; J Revuz; P Wolkenstein
Journal:  J Invest Dermatol       Date:  2000-08       Impact factor: 8.551

2.  Drug-induced epidermal necrolysis: Important new piece to end the puzzle.

Authors:  Jean-Claude Roujeau; Gabriel Bricard; Jean-François Nicolas
Journal:  J Allergy Clin Immunol       Date:  2011-12       Impact factor: 10.793

Review 3.  Toxic epidermal necrolysis.

Authors:  Frederick A Pereira; Adarsh Vijay Mudgil; David M Rosmarin
Journal:  J Am Acad Dermatol       Date:  2007-02       Impact factor: 11.527

4.  Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids.

Authors:  P H Halebian; V J Corder; M R Madden; J L Finklestein; G T Shires
Journal:  Ann Surg       Date:  1986-11       Impact factor: 12.969

5.  Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome.

Authors:  Tai-Ming Ko; Wen-Hung Chung; Chun-Yu Wei; Han-Yu Shih; Jung-Kuei Chen; Chia-Hsien Lin; Yuan-Tsong Chen; Shuen-Iu Hung
Journal:  J Allergy Clin Immunol       Date:  2011-09-14       Impact factor: 10.793

6.  Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis.

Authors:  V Goulden; M J Goodfield
Journal:  Br J Dermatol       Date:  1996-08       Impact factor: 9.302

7.  ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis.

Authors:  B Sassolas; C Haddad; M Mockenhaupt; A Dunant; Y Liss; K Bork; U F Haustein; D Vieluf; J C Roujeau; H Le Louet
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

8.  Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases.

Authors:  Christa Prins; Francisco A Kerdel; R Steven Padilla; Thomas Hunziker; Sergio Chimenti; Isabelle Viard; Davide N Mauri; Kirsten Flynn; Jennifer Trent; David J Margolis; Jean-Hilaire Saurat; Lars E French
Journal:  Arch Dermatol       Date:  2003-01

9.  Transcriptional signature primes human oral mucosa for rapid wound healing.

Authors:  Ramiro Iglesias-Bartolome; Akihiko Uchiyama; Alfredo A Molinolo; Loreto Abusleme; Stephen R Brooks; Juan Luis Callejas-Valera; Dean Edwards; Colleen Doci; Marie-Liesse Asselin-Labat; Mark W Onaitis; Niki M Moutsopoulos; J S Gutkind; Maria I Morasso
Journal:  Sci Transl Med       Date:  2018-07-25       Impact factor: 17.956

10.  Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients.

Authors:  Carlos Gustavo Wambier; Thaís Angélica Hoekstra; Sarah Perillo de Farias Wambier; Roberto Bueno Filho; Fernando Crivelenti Vilar; Renato Soriani Paschoal; Ana Maria Roselino; Marco Andrey Cipriani Frade; Norma Tiraboschi Foss
Journal:  An Bras Dermatol       Date:  2019 Jan-Feb       Impact factor: 1.896

View more
  6 in total

1.  Accuracy of SCORTEN in predicting mortality in toxic epidermal necrolysis.

Authors:  Jerzy Strużyna; Agnieszka Surowiecka; Tomasz Korzeniowski; Patrycja Korulczyk; Lukasz Drozd; Aldona Stachura; Kamil Torres; Andrzej Krajewski
Journal:  BMC Med Inform Decis Mak       Date:  2022-10-19       Impact factor: 3.298

2.  Toxic Epidermal Necrolysis associated with COVID-19 infection: A case report.

Authors:  Lamia Jouhar; Marva Yahya; Sohair Elsiddiq
Journal:  Clin Case Rep       Date:  2022-03-13

3.  Pembrolizumab-induced toxic epidermal necrolysis: case report.

Authors:  Kar Ven Cavan Chow; Connor O'Leary; Fiona Paxton-Hall; Duncan Lambie; Kenneth O'Byrne
Journal:  Oxf Med Case Reports       Date:  2022-03-16

4.  Recurrent Steven-Johnson/Toxic Epidermal Necrolysis Overlap Syndrome.

Authors:  Juan F Toledo-Martinez; Ethel V Galdamez-Carcamo; Francisco J Somoza-Cano; Diego A Padilla-Mantilla; Karina L Alvarenga-Alvarado
Journal:  Cureus       Date:  2022-01-18

5.  Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature.

Authors:  Jing-Yi Wu; Kai Kang; Jing Yi; Bin Yang
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

6.  Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020.

Authors:  Liqin Wang; Sheril Varghese; Fatima Bassir; Ying-Chin Lo; Carlos A Ortega; Sonam Shah; Kimberly G Blumenthal; Elizabeth J Phillips; Li Zhou
Journal:  Front Med (Lausanne)       Date:  2022-08-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.